Zamifenacinfumarate
|
|
|
- CAS号:
- 127308-98-9
- 英文名:
- Zamifenacinfumarate
- 英文别名:
- UK-76654 fumarate;Zamifenacinfumarate;(3R)-1-[2-(1-,3-Benzodioxol-5-yl)ethyl]-3-(diphenylmethoxy)piperidinefumarate;(R)-3-(Benzhydryloxy)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)piperidine fumarate;gut,UK 76654,bowel,inhibit,Inhibitor,Muscarinic acetylcholine receptor,UK-76654,muscarinic,mAChR,motility,syndrome,irritable,Zamifenacin fumarate,Zamifenacin,UK76654,colonic
- 中文名:
- Zamifenacinfumarate
- 中文别名:
- 扎非那星富马酸盐;扎非那新延胡索酸酯;化合物 T13385;(R)-3-(苯甲酰氧基)-1-(2-(苯并[D][1,3]二氧杂环戊烯-5-基)乙基)哌啶富马酸盐
- CBNumber:
- CB81075168
- 分子式:
- C31H33NO7
- 分子量:
- 531.61
- MOL File:
- 127308-98-9.mol
|
|
|
Zamifenacinfumarate化学性质
-
储存条件:
-
Inert atmosphere,2-8°C
-
|
-
溶解度:
-
Soluble to 100 mM in DMSO and to 25 mM in ethanol
-
|
-
形态:
-
Powder
-
|
Zamifenacinfumarate性质、用途与生产工艺
Zamifenacin fumarate (UK-76654 fumarate) 是一种有效的肠道选择性毒蕈碱 M3 受体拮抗剂。Zamifenacin 可显着降低肠易激综合症的结肠蠕动。
Zamifenacin exhibits moderate oral bioavailability (mouse 26%, rat 64%, dog 100%) and C
max
(mouse 92, rat 905, dog 416 ng/mL) following oral administration (mouse 13.2, rat 20 and, dog 5 mg/kg).
Zamifenacin exhibits terminal elimination half-lives (mouse 2.1, rat 6.0 and, dog 1.1 h) due to high plasma clearance (68, 35, and 39 mL/min/kg respectively combined with large volumes of distribution (12.5, 19.0, and 3.5 L/kg respectively) following intravenous administration (mouse 5.3, rat 5.0 and, dog 1.0 mg/kg).
|
Animal Model:
|
Male CDl mice (mean weight 23 g)
|
|
Dosage:
|
5.3 mg/kg for i.v.; 13.2 mg/kg for oral (Pharmacokinetic Analysis)
|
|
Administration:
|
Intravenous administration and oral administration
|
|
Result:
|
Oral bioavailability (26%), C
max
(92 ng/mL), T
1/2
(1.1 h).
|
|
Animal Model:
|
Male and female CD rats (mean weight 210 g)
|
|
Dosage:
|
5.0 mg/kg for i.v.; 20 mg/kg for oral (Pharmacokinetic Analysis)
|
|
Administration:
|
Intravenous administration and oral administration
|
|
Result:
|
Oral bioavailability (64%), C
max
(905 ng/mL), T
1/2
(6.0 h).
|
|
Animal Model:
|
Male and two female beagle dogs (13-16 kg)
|
|
Dosage:
|
1.0 mg/kg for i.v.; 5 mg/kg for oral (Pharmacokinetic Analysis)
|
|
Administration:
|
Intravenous administration and oral administration
|
|
Result:
|
Oral bioavailability (100%), C
max
(416 ng/mL), T
1/2
(1.1 h).
|
Zamifenacinfumarate
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-107649 | Zamifenacinfumarate
Zamifenacin fumarate | 127308-98-9 | 10mM * 1mLin DMSO | 1170元 |
| 2024/04/30 | HY-107649 | Zamifenacinfumarate
Zamifenacin fumarate | 127308-98-9 | 10mg | 1500元 |
127308-98-9, Zamifenacinfumarate 相关搜索:
- C27H29NO3C4H4O4
- 化合物 T13385
- (R)-3-(苯甲酰氧基)-1-(2-(苯并[D][1,3]二氧杂环戊烯-5-基)乙基)哌啶富马酸盐
- 扎非那新延胡索酸酯
- 扎非那星富马酸盐
- 127308-98-9
- gut,UK 76654,bowel,inhibit,Inhibitor,Muscarinic acetylcholine receptor,UK-76654,muscarinic,mAChR,motility,syndrome,irritable,Zamifenacin fumarate,Zamifenacin,UK76654,colonic
- (R)-3-(Benzhydryloxy)-1-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)piperidine fumarate
- UK-76654 fumarate
- (3R)-1-[2-(1-,3-Benzodioxol-5-yl)ethyl]-3-(diphenylmethoxy)piperidinefumarate
- Zamifenacinfumarate